BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 2760841)

  • 1. Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine.
    Flynn DD; Mash DC
    J Pharmacol Exp Ther; 1989 Aug; 250(2):573-81. PubMed ID: 2760841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetrahydroaminoacridine and other allosteric antagonists of hippocampal M1 muscarine receptors.
    Potter LT; Ferrendelli CA; Hanchett HE; Hollifield MA; Lorenzi MV
    Mol Pharmacol; 1989 May; 35(5):652-60. PubMed ID: 2725474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.
    Burke RE
    Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes.
    Watson M; Yamamura HI; Roeske WR
    J Pharmacol Exp Ther; 1986 May; 237(2):411-8. PubMed ID: 3754580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain.
    Norman AB; Creese I
    Mol Pharmacol; 1986 Aug; 30(2):96-103. PubMed ID: 3755499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of alkylating agents on the multiple muscarinic receptor subtypes linked to activation of phospholipase C by carbachol in rat brain cortical membranes.
    Sallés J; Wallace MA; Fain JN
    J Pharmacol Exp Ther; 1993 Feb; 264(2):521-9. PubMed ID: 8437104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic characterization and functional role of muscarinic autoreceptors in the rabbit striatum.
    James MK; Cubeddu LX
    J Pharmacol Exp Ther; 1987 Jan; 240(1):203-15. PubMed ID: 3806384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes.
    Watson M; Roeske WR; Yamamura HI
    J Pharmacol Exp Ther; 1986 May; 237(2):419-27. PubMed ID: 3754581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscarinic receptor heterogeneity in rat central nervous system. II. Brain receptors labeled by [3H]oxotremorine-M correspond to heterogeneous M2 receptors with very high affinity for agonists.
    Gillard M; Waelbroeck M; Christophe J
    Mol Pharmacol; 1987 Jul; 32(1):100-8. PubMed ID: 3600611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscarinic cholinergic receptor binding sites differentiated by their affinity for pirenzepine do not interconvert.
    Gil DW; Wolfe BB
    J Pharmacol Exp Ther; 1986 May; 237(2):577-82. PubMed ID: 3009794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of muscarinic receptor subtypes and their responsiveness in rat brain following chronic atropine administration.
    Lee W; Wolfe BB
    Mol Pharmacol; 1989 Nov; 36(5):749-57. PubMed ID: 2555673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of [3H]pirenzepine binding to muscarinic cholinergic receptors solubilized from rat brain.
    Luthin GR; Wolfe BB
    J Pharmacol Exp Ther; 1985 Jul; 234(1):37-44. PubMed ID: 3839265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tacrine on in vivo release of dopamine and its metabolites in the striatum of freely moving rats.
    Warpman U; Zhang X; Nordberg A
    J Pharmacol Exp Ther; 1996 May; 277(2):917-22. PubMed ID: 8627574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solubilization with digitonin alters the kinetics of pirenzepine binding to muscarinic receptors from rat forebrain and heart.
    Wang JX; Mei L; Yamamura HI; Roeske WR
    J Pharmacol Exp Ther; 1987 Sep; 242(3):981-90. PubMed ID: 3116203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irreversible and quaternary muscarinic antagonists discriminate multiple muscarinic receptor binding sites in rat brain.
    Norman AB; Eubanks JH; Creese I
    J Pharmacol Exp Ther; 1989 Mar; 248(3):1116-22. PubMed ID: 2703964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors.
    Nilvebrant L
    Acta Pharmacol Toxicol (Copenh); 1986; 59 Suppl 1():1-45. PubMed ID: 3524114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [3H]Pirenzepine and [3H]quinuclidinyl benzilate binding to brain muscarinic cholinergic receptors. Differences in measured receptor density are not explained by differences in receptor isomerization.
    Luthin GR; Wolfe BB
    Mol Pharmacol; 1984 Sep; 26(2):164-9. PubMed ID: 6548291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscarinic receptors on rat isolated colonic epithelial cells. A correlation between inhibition of [3H]quinuclidinyl benzilate binding and alteration in ion transport.
    Zimmerman TW; Binder HJ
    Gastroenterology; 1982 Dec; 83(6):1244-51. PubMed ID: 6127277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the involvement of multiple muscarinic receptor subtypes in the activation of phosphoinositide metabolism in rat cerebral cortex.
    Forray C; el-Fakahany EE
    Mol Pharmacol; 1990 Jun; 37(6):893-902. PubMed ID: 2163015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of binding of muscarinic receptor antagonists in rat brain homogenates.
    Lee JH; el-Fakahany EE
    J Pharmacol Exp Ther; 1985 Jun; 233(3):707-14. PubMed ID: 3839264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.